Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
14/11/2025
The CEO of Citigroup is very optimistic about the prospects for 2026.
Latest
4 m ago
In the year, the fundraising size of 11 FOFs all exceeded 20 billion.
4 m ago
Goldman Sachs Group pointed out that China's large-scale construction of power generation capacity will give it an advantage over the United States in the expansion race of artificial intelligence data centers. The Goldman Sachs report stated that the United States lacks effective backup power capacity, which could potentially become a bottleneck for further development of data centers; in contrast, China already has large-scale grid-connected backup capacity and is expected to further expand.
5 m ago
Minhua Holdings plans to split Remai Technology through the New Third Board listing method, but still needs approval from the National Equities Exchange and Quotations Company.
7 m ago
"Shenzhen AI forecaster 'A Lan' goes live to ensure air quality for the Fifteenth National Games and Paralympics."
9 m ago
Hong Kong stocks soar | Sansheng Pharmaceuticals (01530.HK) up nearly 5% again, institutions say Pfizer's 707 global clinical trial progress exceeds market expectations.
See all latest